Dapagliflozin Halves Hyperkalemia in Some HF Patients Dapagliflozin Halves Hyperkalemia in Some HF Patients

Dapagliflozin decreases moderate to severe hyperkalemia in heart failure (HF) patients treated with a mineralocorticoid receptor antagonist (MRA), a prespecified analysis of DAPA-HF data show.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news